Cost-effectiveness of caplacizumab in immune thrombotic thrombocytopenic purpura in the United States.
Considering willingness-to-pay thresholds of $150,000 to $200,000, the addition of caplacizumab to PEX+IS may be cost-effective compared with PEX+IS alone for the treatment of iTTP in a US setting.
Authors
- Alix Arnaud (ORCID: https://orcid.org/0000-0003-1193-4258)
- Sean D. Sullivan (ORCID: https://orcid.org/0000-0003-3052-6540)
- Shruti Chaturvedi (ORCID: https://orcid.org/0000-0001-6832-2389)
- Preety Gautam
Institutions
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Sanofi (France) (FR)
- Office Of Health Economics (GB)
- Sanofi (India) (IN)
Publication Details
- Journal
- PubMed
- Published
- 2025-03-01
- DOI
- https://doi.org/10.18553/jmcp.2025.31.3.277
- Citations
- 1
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.80